{"entity":"astrazeneca","id":"ent_astrazeneca","name":"AstraZeneca","wikidata":"Q731938","page":"https://asof.is/record/astrazeneca","summary":"AstraZeneca is a British-Swedish pharmaceutical company, headquartered in Cambridge. Its CEO is Pascal Soriot, since 2012. It reported revenue of $54.07B for the period ended December 31, 2024.","title":"AstraZeneca: CEO Pascal Soriot, revenue $54.07B","key_facts":[{"label":"CEO","value":"Pascal Soriot","note":"since 2012","claim":"clm_5E921CD2E098"},{"label":"Headquarters","value":"Cambridge","claim":"clm_6B4DC8E0E36A"},{"label":"Revenue","value":"$54.07B","recorded":"54,073,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_5BDDB85A5719"},{"label":"Ticker","value":"AZN · NYSE","claim":"clm_7F36A4D2B72F"}],"faq":[{"question":"Who is the CEO of AstraZeneca?","answer":"Pascal Soriot, since 2012, as the AsOf record states with its sources."},{"question":"Where is AstraZeneca headquartered?","answer":"Cambridge."},{"question":"What is AstraZeneca's revenue?","answer":"$54.07B for the period ended December 31, 2024."}],"as_of":"2025-11-08","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/astrazeneca/ceo","md":"https://asof.is/record/astrazeneca/ceo.md","json":"https://asof.is/v1/entities/astrazeneca/ceo"},{"predicate":"headquarters","page":"https://asof.is/record/astrazeneca/headquarters","md":"https://asof.is/record/astrazeneca/headquarters.md","json":"https://asof.is/v1/entities/astrazeneca/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/astrazeneca/revenue","md":"https://asof.is/record/astrazeneca/revenue.md","json":"https://asof.is/v1/entities/astrazeneca/revenue"},{"predicate":"net_income","page":"https://asof.is/record/astrazeneca/net_income","md":"https://asof.is/record/astrazeneca/net_income.md","json":"https://asof.is/v1/entities/astrazeneca/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/astrazeneca/operating_income","md":"https://asof.is/record/astrazeneca/operating_income.md","json":"https://asof.is/v1/entities/astrazeneca/operating_income"}],"products":[],"coverage":{"entity":"astrazeneca","name":"AstraZeneca","kind":"organization","sources":[{"source":"wikidata","item":"Q731938","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":901832,"ticker":"AZN","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":65,"open":13,"retracted":0,"first":"1995-03-13","predicates":{"total_assets":{"claims":11,"open":1,"kind":"fact"},"revenue":{"claims":11,"open":1,"kind":"fact"},"operating_income":{"claims":11,"open":1,"kind":"fact"},"net_income":{"claims":11,"open":1,"kind":"fact"},"total_equity":{"claims":12,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":2,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":65,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_5E921CD2E098","predicate":"ceo","value":"Pascal Soriot","valid_from":"2012-10-01","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca ceo: Pascal Soriot\", as of 2012-10-01. Claim clm_5E921CD2E098, https://asof.is/claim/clm_5E921CD2E098, accessed 2026-11-09. Source: https://www.astrazeneca.com/our-company/leadership.html.","url":"https://asof.is/claim/clm_5E921CD2E098","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.astrazeneca.com/our-company/leadership.html","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.sec.gov/Archives/edgar/data/0000901832/000095010312004497/dp32579_6k.htm","tier":"primary","publisher":"sec.gov","published_at":null},{"url":"https://www.wikidata.org/wiki/Q731938","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012. Simon Lowth will remain as AstraZeneca’s Interim Chief Executive Officer until Pascal Soriot joins.","url":"https://www.sec.gov/Archives/edgar/data/0000901832/000095010312004497/dp32579_6k.htm"}},{"id":"clm_8820826D4245","predicate":"cik","value":"0000901832","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca cik: 0000901832\", undated. Claim clm_8820826D4245, https://asof.is/claim/clm_8820826D4245, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_8820826D4245","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_433F982364C7","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca fiscal year end: 12-31\", undated. Claim clm_433F982364C7, https://asof.is/claim/clm_433F982364C7, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_433F982364C7","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_6B4DC8E0E36A","predicate":"headquarters","value":"Cambridge","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca headquarters: Cambridge\", undated. Claim clm_6B4DC8E0E36A, https://asof.is/claim/clm_6B4DC8E0E36A, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_6B4DC8E0E36A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_43376D897A1F","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca listed on: NYSE\", undated. Claim clm_43376D897A1F, https://asof.is/claim/clm_43376D897A1F, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_43376D897A1F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_DCF412B5DDDA","predicate":"net_income","value":"7,041,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca net income: 7,041,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_DCF412B5DDDA, https://asof.is/claim/clm_DCF412B5DDDA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_DCF412B5DDDA","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7F0BFE9EB1CD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_3994638C1B14","predicate":"operating_income","value":"10,003,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca operating income: 10,003,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_3994638C1B14, https://asof.is/claim/clm_3994638C1B14, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_3994638C1B14","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_763AA2791DE9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_CC0A4381A0A0","predicate":"registrant_name","value":"ASTRAZENECA PLC","valid_from":"1999-02-05","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca registrant name: ASTRAZENECA PLC\", as of 1999-02-05. Claim clm_CC0A4381A0A0, https://asof.is/claim/clm_CC0A4381A0A0, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_CC0A4381A0A0","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_5BDDB85A5719","predicate":"revenue","value":"54,073,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca revenue: 54,073,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_5BDDB85A5719, https://asof.is/claim/clm_5BDDB85A5719, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_5BDDB85A5719","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_75285D1846DF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_26C4F27CEF84","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_26C4F27CEF84, https://asof.is/claim/clm_26C4F27CEF84, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_26C4F27CEF84","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_8352C183E226","predicate":"state_of_incorporation","value":"X0","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca state of incorporation: X0\", undated. Claim clm_8352C183E226, https://asof.is/claim/clm_8352C183E226, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_8352C183E226","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7F36A4D2B72F","predicate":"ticker","value":"AZN","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca ticker: AZN\", undated. Claim clm_7F36A4D2B72F, https://asof.is/claim/clm_7F36A4D2B72F, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832.","url":"https://asof.is/claim/clm_7F36A4D2B72F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_F05CE2B1D291","predicate":"total_assets","value":"104,035,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total assets: 104,035,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_F05CE2B1D291, https://asof.is/claim/clm_F05CE2B1D291, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_F05CE2B1D291","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B12E0C1D9275","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2024, filed 2025-02-18"}},{"id":"clm_702A322E3B09","predicate":"total_equity","value":"40,871,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-18","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AstraZeneca total equity: 40,871,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_702A322E3B09, https://asof.is/claim/clm_702A322E3B09, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm.","url":"https://asof.is/claim/clm_702A322E3B09","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_327B10FB292B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/901832/000110465925014750/0001104659-25-014750-index.htm","tier":"primary","publisher":"SEC EDGAR 20-F FY2024","published_at":"2025-02-18T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2024, filed 2025-02-18"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing"}}}